Lexeo Therapeutics, Inc. (LXEO)
| Market Cap | 342.94M +21.9% |
| Revenue (ttm) | n/a |
| Net Income | -87.27M |
| EPS | -1.15 |
| Shares Out | 82.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,099,053 |
| Open | 4.270 |
| Previous Close | 4.160 |
| Day's Range | 4.140 - 4.380 |
| 52-Week Range | 3.990 - 10.990 |
| Beta | 1.50 |
| Analysts | Strong Buy |
| Price Target | 20.30 (+385.65%) |
| Earnings Date | Nov 4, 2026 |
About LXEO
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for LXEO stock is "Strong Buy." The 12-month stock price target is $20.3, which is an increase of 385.65% from the latest price.
News
Lexeo Therapeutics Transcript: 2026 Global Healthcare Conference
Lead programs in Friedreich's ataxia and PKP2 cardiomyopathy show strong efficacy signals, with pivotal and phase I studies progressing toward key readouts in 2026–2027. Streamlined CMC and commercial strategies target heart failure specialists, supported by a solid cash runway into 2028.
Lexeo Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The discussion highlighted progress in gene therapies for FA and PKP2-ACM, emphasizing robust clinical data, precise endpoints, and scalable manufacturing. Durable cardiac and neurologic improvements, broad patient eligibility, and efficient commercialization strategies position these therapies for significant impact.
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, tod...
Lexeo Therapeutics reports Q2 EPS (30c), consensus (28c)
“We closed the second quarter with significant momentum, highlighted by the initiation of SUNRISE-FA 2, the pivotal study for LX2006 in Friedreich ataxia cardiomyopathy,” said R. Nolan Townsend, Chief...
Lexeo Therapeutics Slides: Corporate presentation
Lexeo Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first ...
Lexeo Therapeutics Earnings release: Q2 2026
Lexeo Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Lexeo Therapeutics Quarterly report: Q2 2026
Lexeo Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Lexeo Therapeutics management to meet with Cantor
Meeting to be held in New York on August 13 hosted by Cantor.
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM
Lexeo Therapeutics Transcript: Fireside chat
The discussion highlighted robust progress in the phase III FACM program, with strong clinical data, regulatory alignment, and a well-powered pivotal study. Durable improvements in cardiac and neurologic endpoints were noted, and the company is well-funded to reach key milestones.
Lexeo Therapeutics Transcript: AGM 2026
The meeting addressed the election of directors and auditor ratification, with both proposals passing. No questions were submitted by stockholders, and final voting results will be filed on Form 8-K.
Lexeo Therapeutics price target lowered to $9 from $12 at JPMorgan
JPMorgan lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $9 from $12 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect…
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies
Lexeo Therapeutics Transcript: Investor update
A pivotal trial for LX2006 in Friedreich's ataxia is set to begin, targeting accelerated approval with a robust design and strong phase I/II data showing significant cardiac and neurologic benefits. Enrollment is progressing, with top-line results expected in 2027 and a BLA filing in 2028.
Lexeo Therapeutics Slides: Investor update
Lexeo Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Lexeo Therapeutics Press release: Investor update
Lexeo Therapeutics issued a press release on June 15, 2026, disclosing material business information to investors.
Lexeo finalizes SUNRISE-FA 2 pivotal trial protocol, statistical analysis plan
Lexeo Therapeutics (LXEO) announced that the company has finalized the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan intended to provide clinical evidence to support the submission...
Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia
SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design
Lexeo Therapeutics Slides: Corporate presentation
Lexeo Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 14, 2026.
Lexeo Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Gene therapy programs show strong efficacy in Friedreich's ataxia and PKP2 cardiomyopathy, with pivotal studies and regulatory milestones on track. Manufacturing is optimized, safety profiles are favorable, and strategic planning addresses both U.S. and European pathways.
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, toda...
Lexeo Therapeutics reports Q1 EPS (25c), consensus (30c)
“We continued to make steady progress across our key priorities in the first quarter of 2026. As we work with the FDA to finalize the SUNRISE-FA 2 pivotal study protocol,…
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across cardiac genetic medicine...
Lexeo Therapeutics Quarterly report: Q1 2026
Lexeo Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.